May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
The Novel Agent PPP Is More Effective Than Traditional Chemotherapeutic Drugs in Causing Uveal Melanoma Cell Death in vitro
Author Affiliations & Notes
  • M.–A. Economou
    Karolinska Intitutet, Stockholm, Sweden
  • C. All–Ericsson
    Karolinska Intitutet, Stockholm, Sweden
  • S. Seregard
    Karolinska Intitutet, Stockholm, Sweden
  • L. Girnita
    Karolinska Intitutet, Stockholm, Sweden
  • O. Larsson
    Karolinska Intitutet, Stockholm, Sweden
  • Footnotes
    Commercial Relationships  M. Economou, None; C. All–Ericsson, None; S. Seregard, None; L. Girnita, None; O. Larsson, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 2228. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M.–A. Economou, C. All–Ericsson, S. Seregard, L. Girnita, O. Larsson; The Novel Agent PPP Is More Effective Than Traditional Chemotherapeutic Drugs in Causing Uveal Melanoma Cell Death in vitro . Invest. Ophthalmol. Vis. Sci. 2006;47(13):2228.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : We have previously shown that the cyclolignan picropodophyllin (PPP) efficiently blocks the insulin–like growth facotor–1 receptor (IGF–1R) and causes cell death in uveal melanoma cell lines. Further, PPP induces significant tumor regression in animal models. In this study we compared the effectiveness of PPP with imatinab mesylate (Gleevec) and more traditional antineoplastic agents such as 5–fluorouracil (5–FU), doxorubicin and cisplatin and investigated the potential synergistic effects of these drugs.

Methods: : Four different uveal melanoma cell lines (OCM–1, OCM–3, OCM–8, 92–1) were treated with different concentrations of PPP alone and in combination with Gleevec, 5–FU, doxorubicin and cisplatin for 48 hrs. Cell survival was assessed by XTT. Cell viability determinations were performed using the Cell proliferation kit II.

Results: : The IC50 of PPP for the four different ocular melanoma cell lines were between 0.015–0.035 µM, for Gleevec 0.18–0.25 µM, for 5–FU 3–5mM, for Doxorubicin 8–10 µM and for Cisplatin 1–6 µM. A concentration of 0.04 µM PPP reduced cell survival by 60–90%. Generally, the OCM–8 cell line was generally more sensitive for exposure of PPP, Cisplatine and Imitanib. There was no synergistic effect for any combination of these drugs in any of the cell lines

Conclusions: : PPP alone efficiently decreased viability of the 4 uveal melanoma cell lines studied.

Keywords: tumors • melanoma • drug toxicity/drug effects 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.